These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24399184)

  • 41. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
    Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
    Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus.
    Bortoluzzi A; Valesini G; D'Angelo S; Frediani B; Bazzichi L; Afeltra A; Paolazzi G; Doria A; Meroni PL; Govoni M
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii32-vii41. PubMed ID: 30289538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update of French society for rheumatology recommendations for managing rheumatoid arthritis.
    Daien C; Hua C; Gaujoux-Viala C; Cantagrel A; Dubremetz M; Dougados M; Fautrel B; Mariette X; Nayral N; Richez C; Saraux A; Thibaud G; Wendling D; Gossec L; Combe B
    Joint Bone Spine; 2019 Mar; 86(2):135-150. PubMed ID: 30315988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis.
    Coury FF; Weinblatt ME
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S9-12. PubMed ID: 21044426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α.
    Benedek TG
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S3-8. PubMed ID: 21044425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting methotrexate resistance in rheumatoid arthritis patients.
    Yu MB; Firek A; Langridge WHR
    Inflammopharmacology; 2018 Jun; 26(3):699-708. PubMed ID: 29532212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey.
    Saraux A; Devauchelle-Pensec V; Engerran L; Flipo RM
    J Rheumatol; 2006 Jul; 33(7):1258-65. PubMed ID: 16783865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.
    Kudo-Tanaka E; Shimizu T; Nii T; Teshigawara S; Yoshimura M; Watanabe A; Tsuji S; Tsuboi H; Hirao M; Yura A; Harada Y; Sueishi M; Suenaga Y; Chiba N; Tonai T; Saisho K; Ogata A; Matsushita M; Hashimoto J; Ohshima S; Tohma S; Saeki Y
    Mod Rheumatol; 2015; 25(6):831-6. PubMed ID: 25800638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The dimeric form of HLA-G molecule is associated with the response of early rheumatoid arthritis (ERA) patients to methotrexate.
    Rizzo R; Farina I; Bortolotti D; Galuppi E; Padovan M; Di Luca D; Govoni M
    Clin Rheumatol; 2017 Mar; 36(3):701-705. PubMed ID: 27778096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Methotrexate treatment of rheumatoid arthritis in Denmark].
    de Thurah A; Nørgaard M; Stengaard-Pedersen K
    Ugeskr Laeger; 2011 Sep; 173(36):2187-9. PubMed ID: 21893001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF; Sanchez-Yamamoto D; Bush TM
    J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.
    Schiff M; Jaffe J; Freundlich B; Madsen P
    Expert Rev Med Devices; 2014 Sep; 11(5):447-55. PubMed ID: 24934630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
    Kotrych D; Dziedziejko V; Safranow K; Pawlik A
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
    Mena-Ramírez JP; Salazar-Páramo M; Dávalos-Rodríguez IP
    Gac Med Mex; 2008; 144(5):449-51. PubMed ID: 19043967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.